Allogeneic Thymocyte-Depleted Thymus Tissue-Agdc: Side Effects, Uses & Monitoring
RETHYMIC® is indicated for immune reconstitution in pediatric patients with congenital athymia.
- Data source
- FDA labeling via NIH DailyMed (label e0022c28…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
RETHYMIC® is indicated for immune reconstitution in pediatric patients with congenital athymia.
Frequently Asked Questions
What is Allogeneic Thymocyte-Depleted Thymus Tissue-Agdc used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Allogeneic Thymocyte-Depleted Thymus Tissue-Agdc?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Allogeneic Thymocyte-Depleted Thymus Tissue-Agdc require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Allogeneic Thymocyte-Depleted Thymus Tissue-Agdc.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.